NCT04069442

cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

• Status: Withdrawn
• Phase: —
• Study type: Observational
• Enrollment: 0 (actual)
• Sponsor: University Hospital, Grenoble · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The response rate of immune checkpoint inhibitors remains relatively low and the identification of the new predictive biomarkers is necessary. The rare population of cDC1 is very interesting, as its mouse counterparts is essential for the cross presentation of tumor-associated antigens, tumor immunity and response to immunotherapies. Their role in humans has not been studied. This proposal aims to study the prognostic role of cDC1 in a cohort of patients with advanced NSCLC, possibly demonstrating their positive predictive value of immune checkpoint inhibitors response.

Detailed description

Multicenter study aiming to collect patient's clinical data retrospectively and their histological samples prospectively. The cohort will include: * 30 patients PD-L1 \> 50% treated with pembrolizumab in first line and having a progression free survival ≥ 3 months * 30 patients PD-L1 \> 50% treated with pembrolizumab in first line and having a progression free survival \< 3 months * 30 patients PD-L1 \< 50% treated with cisplatin-based chemotherapy in first line

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
OTHER	This is a non-interventional study	This is a non-interventional study

Timeline

• Start date: 2020-06-01
• Primary completion: 2020-09-01
• Completion: 2020-09-01
• First posted: 2019-08-28
• Last updated: 2021-04-01

Locations

1 site across 1 country: France